Introduction Risk-reducing salpingo-oophorectomy (RRSO) is one of key prevention strategies for female BRCA1/2 mutation carriers. The purpose of this study was to identify the factors associated with uptake RRSO among patients with BRCA1/2 mutation.
Methods We reviewed the medical records of 786 patients who underwent BRCA1/2 gene testing at Ewha Womans University Mokdong Hospital from June 13, 2007 to July 28, 2020. Socio-demographic and clinical characteristics were compared between non-RRSO group and RRSO group, and the factors affecting the uptake of RRSO were analyzed.
Results Among the final study population of 70 patients with BRCA1/2 mutation, 39 (55.7%) and 31 (44.3%) were in the non-RRSO group and RRSO group, respectively. There were significant differences in age (41.38±13.65 yr vs. 44.35±7.78 yr, P=0.042), marital status (30.8% vs. 3.2% in single; 66.7% vs. 87.1% in married, P=0.002), parity (43.6% vs. 6.5% in nullipara; 53.4% vs. 93.6% in primi-/multipara, P<0.001) and employment status (41.0% vs. 32.3%, P=0.019) between non-RRSO group and RRSO group. However, no significant differences between the two groups were observed in personal and familial histories of breast or gynecologic cancer. Univariate analysis found significant associations between RRSO uptake and parity, marital and employment status. In RRSO group, the median time interval between BRCA1/2 testing and RRSO uptake was 8.8 (6.2–19.6) months. No subsequent cancer cases occurred in either group during the surveillance.
Conclusion/Implications RRSO uptake in patients with BRCA1/2 mutation was affected by parity, marital and employment status. These findings may be of useful assistance to clinicians when counseling patients with BRCA1/2 mutations receiving RRSO.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.